6 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary FibrosisFibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, idiopathic pulmonary fibrosis, interstitial lung disease, lung disorder, pulmonary fibrosis, respiratory system disorderRecruitingPhase 22026-10-09NCT07284459
An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut SyndromeCongenital, Hereditary, and Neonatal Diseases and Abnormalities, Epileptic Syndromes, Lennox-Gastaut syndrome, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, brain disorder, central nervous system disorder, epilepsy, hereditary disease, nervous system disorder, visual epilepsyRecruitingPhase 32026-10-09NCT05066217
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDPChronic Disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, autoimmune disease, autoimmune disorder of the nervous system, chronic inflammatory demyelinating polyradiculoneuropathy, demyelinating disease, immune system disorder, nervous system disorder, neuromuscular disease, peripheral nervous system disorder, polyneuropathy, polyradiculoneuropathyRecruitingPhase 32026-09-24NCT06920004
A Study of Eptinezumab in Pediatric Participants With Episodic MigraineEpisodic MigraineRecruitingPhase 32026-09-09NCT05897320
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia GravisMyasthenia Gravis, Ocular, Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, autoimmune disease, autoimmune disorder of the nervous system, immune system disorder, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, paraneoplastic syndromeActive, not recruitingPhase 32026-07-02NCT06558279
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migrainebrain disorder, central nervous system disorder, headache disorder, hypnic headache, migraine disorder, nervous system disorderRecruitingPhase 32026-06-12NCT05164172